Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Argent Biopharma's Enterprise Value is A$8.93 Mil.
Argent Biopharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$-16.53 Mil. Therefore, Argent Biopharma's EV-to-EBIT ratio for today is -0.54.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Argent Biopharma's Enterprise Value is A$8.93 Mil.
Argent Biopharma's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was A$-15.39 Mil. Therefore, Argent Biopharma's EV-to-EBITDA ratio for today is -0.58.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Argent Biopharma's Enterprise Value is A$8.93 Mil.
Argent Biopharma's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was A$1.67 Mil. Therefore, Argent Biopharma's EV-to-Revenue ratio for today is 5.35.
Argent Biopharma Enterprise Value Historical Data
The historical data trend for Argent Biopharma's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Argent Biopharma's Enterprise Value
For the Drug Manufacturers - Specialty & Generic subindustry, Argent Biopharma's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Argent Biopharma's Enterprise Value Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Argent Biopharma's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Argent Biopharma's Enterprise Value falls into.
Argent Biopharma Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Argent Biopharma's Enterprise Value for the fiscal year that ended in Jun. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Argent Biopharma (ASX:RGT) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Argent Biopharma's current Enterprise Value is A$8.93 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Argent Biopharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$-16.53 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Argent Biopharma's current Enterprise Value is A$8.93 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Argent Biopharma's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was A$-15.39 Mil.
Argent Biopharma's current Enterprise Value is A$8.93 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Argent Biopharma's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was A$1.67 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Argent Biopharma Enterprise Value Related Terms
Thank you for viewing the detailed overview of Argent Biopharma's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
MGC Pharmaceuticals Ltd is a biopharma company with a Nature to Medicine strategy at the forefront of the emerging phytocannabinoid and plant-derived medicine markets. The company's mission is to build an innovative, global bio-pharma company providing standardized, affordable plant-derived medicines of the highest regulatory compliance for targeted global markets.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ASX:RGT has been successfully added to your 